Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

FDA grants priority review to Lucentis sBLA for myopic CNV

Oct. 11, 2016

FDA issues complete response letter for AC-170 NDA

Oct. 10, 2016

Lee's Pharmaceutical licenses rights to Resolvine ER in Greater China and South East Asia

Oct. 10, 2016

Santen, RIKEN and FBRI to develop novel retinal disease treatments

Oct. 7, 2016

Ocular Therapeutix initiates first phase III trial of OTX-TP for glaucoma and ocular hypertension

Oct. 5, 2016

Regeneron reports topline data from phase II trial of aflibercept/rinucumab in wet AMD

Oct. 3, 2016

Mikeluna approved in Japan for glaucoma and intraocular hypertension

Sep. 30, 2016

Recombinant human lubricin improves symptoms of dry eye disease

Sep. 30, 2016

Cellular Dynamics International launches new venture, Opsis Therapeutics

Sep. 30, 2016

Johnson & Johnson to acquire Abbott Medical Optics

Sep. 19, 2016

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 6, 2025
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology
BioWorld
About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...